jRCT1031250785招募中不适用
A Prospective Single-Center Exploratory Study of Letermovir for Cytomegalovirus Prophylaxis in Perioperative Liver Transplantation
未提供0 个研究点目标入组 30 人开始时间: 待定
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •(1) No history of CMV treatment.
- •(2) Scheduled to undergo liver transplantation (brain-dead or living donor).
- •(3) Patients at intermediate or high risk for CMV infection.
- •(4) Age: 18 years or older at the time of obtaining consent.
- •(5) Gender: Any.
- •(6) Patients who have received a full explanation regarding participation in this study, fully understood the contents, and provided written informed consent of their own free will (or via a legally acceptable representative).
- •(7) Patients capable of outpatient visits according to the study schedule.
排除标准
- •(1) History of severe drug allergies such as anaphylactic shock or history of severe side effects.
- •(2) Patients using concomitant drugs contraindicated in the package insert of Prevymis (pimozide, ergotamine tartrate/anhydrous caffeine/isopropylantipyrine, dihydroergotamine, methylergometrine, ergometrine).
- •(3) Any other patients deemed unsuitable for participation in this study by the Principal Investigator or Sub-investigator.
研究者
相似试验
招募中
4 期
A Randomised, Open-Label, Single-Centre, Study to Evaluate the Bioequivalence of LanifibranorNon-alcoholic steatohepatitis2025-524385-18-00Inventiva30
招募中
2 期
A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus lomustine in patients with glioblastoma at first progressionGlioblastoma2022-501822-39-00Philogen S.p.A.113
已完成
1 期
A Phase 1 Randomized Study to Evaluate the Effect of Food on the Bioavailability of BMS-986158 in Participants with Advanced Solid Tumors.2023-506661-65-00Bristol-Myers Squibb Services Unlimited Company40
招募中
1 期
An exploratory study to investigate the effect of FE 999302 when given together with follitropin delta during controlled ovarian stimulation2023-507630-25-00Ferring Pharmaceuticals A/S600
已完成
1 期
A SINGLE-CENTER, OPEN-LABEL, TWO-PERIOD STUDY TO INVESTIGATE THE EFFECT OF MULTIPLE DOSE ITRACONAZOLE, A STRONG CYP3A INHIBITOR, ON THE PHARMACOKINETICS OF A SINGLE 30 MG DOSE OF RO7269162 IN HEALTHY PARTICIPANTS2024-510732-52-00F. Hoffmann-La Roche AG18